Paterson reappointed as ANSTO's CEO

The CEO of the Australian Nuclear Science and Technology Organisation (ANSTO), Dr Adi Paterson, has been reappointed to his position for the next five years.

The news comes two years after his previous reappointment, in March 2014.

Since Dr Paterson commenced his tenure as CEO in March 2009, ANSTO has significantly expanded its national and international impact as the home of Australia’s nuclear science expertise. Moving forward, Dr Paterson plans to build on the major programs and projects that are helping drive ANSTO’s growth, including:

• the $168.8 million ANSTO Nuclear Medicine project, which will come online in coming months and see ANSTO more than triple its production of potentially lifesaving nuclear medicines;
• ANSTO’s assumption of operational control of the Australian Synchrotron;
• improving the organisational culture of ANSTO and continuing ANSTO’s outward-focused strategies; and
• continuing to build, foster and reinforce ANSTO’s strong relationships with nuclear science, governmental, research and global stakeholders.

ANSTO Chair Jim McDowell, who formally reappointed Dr Paterson last month after endorsement from cabinet, said it was the latter’s leadership, achievements to date and strong vision for ANSTO’s future that have made the board confident of his continued leadership.

“Dr Paterson has lead ANSTO exceptionally well, and will continue to do so,” said McDowell. “With Dr Paterson at the helm, we are well positioned to continue to deliver strong outcomes for Australia.”

Image caption: Dr Adi Paterson.